MarketVIEW: Chikungunya virus

Chikungunya virus (CHIK), which is endemic to SE Asia and Africa is mosquito borne virus contributes to excess morbidity and mortality during intermittent intense outbreaks. Because there is no specific treatment for CHIK infection many organizations, including biotechs and the US/French military have considered the prospect for a prophylatic vaccine which could be used in stationed troops, travellers and vulnerable residents of endemic areas.

This expert report comprises of two deliverables 1) A commercial summary presentation and 2) An Excel-based commercial forecast model which details potential demand (doses) and gross sales revenues ($USD) in potential target markets for a prophylatic Chikungunya vaccine. For each target market characteristics and model assumptions are clearly presented along with relevant cases studies of other vaccines currently licensed for travelling populations and private markets of SE Asia. The report has been structured to provide expert guidance as to the commercial viability of a CHIK vaccine.

Please note: this is delivered as a Zip file.